April 2024 in “Journal of clinical medicine” Effective treatment guidelines for frontal fibrosing alopecia are still unclear.
Alopecia Areata has no cure, treatments are limited, and the condition often recurs, but new therapies like JAK inhibitors show promise.
11 citations
,
January 2022 in “Journal der Deutschen Dermatologischen Gesellschaft” Alopecia areata is a chronic condition causing hair loss, with new treatments targeting the immune system showing promise.
4 citations
,
November 2020 in “Acta Dermato Venereologica” Tofacitinib effectively improved severe skin symptoms in a patient with Hypohidrotic Ectodermal Dysplasia.
3 citations
,
November 2024 in “Acta Dermato Venereologica” Online articles about alopecia areata are too hard to understand and need to be clearer.
2 citations
,
November 2014 in “The journal of investigative dermatology/Journal of investigative dermatology” Oral tofacitinib can treat both psoriasis and alopecia universalis by normalizing inflammatory pathways.
1 citations
,
January 2017 in “Springer eBooks” Understanding the immune-related causes of Alopecia Areata has led to potential treatments like JAK inhibitors.
January 2026 in “International Journal of All Research Education & Scientific Methods” Alopecia is caused by various factors, and new treatments like gene editing and regenerative medicine offer hope for personalized hair regrowth solutions.
November 2025 in “Biomedicines” JAK1 inhibitors can help reduce itchiness in atopic dermatitis.
September 2025 in “International Journal of Science and Research (IJSR)” Stress causes hair loss by disrupting hair growth cycles, and combining medical and cosmetic treatments can help manage it.
Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.
Ritlecitinib is a new treatment for severe hair loss in people 12 and older.
April 2025 in “Vestnik dermatologii i venerologii” JAK inhibitors like tofacitinib are effective and safer for severe alopecia areata than glucocorticosteroids.
March 2025 in “Meditsinskiy sovet = Medical Council” Dupilumab and oral JAK inhibitors are effective for treating alopecia areata with atopic diseases.
April 2024 in “Expert opinion on investigational drugs” JAK inhibitors are safe and effective for treating moderate-to-severe alopecia areata.
May 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” A potential treatment for atopic dermatitis could be to increase PADI1 expression to improve skin barrier function.
September 2022 in “IP Indian journal of clinical and experimental dermatology” Doctors should prescribe Minoxidil, Finasteride, and Dutasteride for treating androgenetic alopecia.
1 citations
,
February 2025 in “International Journal of Dermatology” Abrocitinib may effectively treat Lichen Planopilaris.
15 citations
,
December 2019 in “European Journal of Dermatology” Low-dose tofacitinib is effective and cheaper for severe alopecia areata.
14 citations
,
March 2017 in “Genes and immunity” Certain microRNAs may help treat alopecia areata by targeting immune pathways.
10 citations
,
June 2017 in “Experimental Dermatology” New hair loss treatments have evolved from understanding hair biology and patient needs.
2 citations
,
March 2025 in “International Journal of Dermatology” Tralokinumab successfully treated alopecia areata in a patient with atopic dermatitis.
2 citations
,
January 2020 in “Enlighten: Theses (The University of Glasgow)” Alopecia areata is an autoimmune disease causing hair loss, and targeting macrophages may help treat it.
1 citations
,
April 2025 in “Skin Health and Disease” Combining delgocitinib ointment with excimer laser can effectively treat severe alopecia areata.
July 2024 in “Journal of Investigative Dermatology” CD8+ T cells expand significantly in alopecia areata, suggesting new treatment targets.
April 2024 in “Frontiers in physiology” Immune cells are crucial for hair growth and preventing hair loss.
25 citations
,
March 2021 in “Australasian Journal of Dermatology” Ustekinumab successfully treated a man's resistant skin condition when other treatments failed.
49 citations
,
March 2017 in “Journal of the American Academy of Dermatology” Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.
27 citations
,
January 2020 in “Experimental Dermatology” Immune cells affect hair growth and could lead to new hair loss treatments.
3 citations
,
February 2024 in “Journal of the American Academy of Dermatology” Topical tofacitinib cream may help treat certain hair loss conditions with fewer risks.